



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 04 Jul 2022 (#26)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

[NOT-CA-22-109](#) Notice of Pre-Application Webinar for Precision Approaches in Radiation Synthetic Combinations (PAIRS): [PAR-22-198](#) (R01 Clinical Trial Optional), [PAR-22-199](#) (R21 Clinical Trial Optional). The National Cancer Institute (NCI) will hold a public pre-application webinar on August 3, 2022, from 3:00 pm to 5:00 pm EDT. The National Cancer Institute (NCI) will hold a public pre-application webinar on August 3, 2022, from 3:00 pm to 5:00 pm EDT. NCI staff members involved in managing this program will assist potential applicants by explaining the goals and objectives of this initiative and answering questions from attendees. Prospective applicants are encouraged to submit their questions or comments to hongj@mail.nih.gov in advance of the webinar. Registration: Potential applicants interested in participating in the webinar should send an email to: Ms. Julie Hong (Hongj@mail.nih.gov) to obtain registration information no later than 5:00 p.m. (EDT) on August 1, 2022.

[NOT-EB-22-007](#) Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development. The NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative intends to issue a Funding Opportunity Announcement (FOA) for BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. First Estimated Application Due Date: October 13, 2022.

Notice of Special Interest (NOSI)

[NOT-OD-22-159](#) Notice of Special Interest (NOSI): Administrative Supplements to Support Research on Preventive Interventions with Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional). The NIH Office of Disease Prevention (ODP) within the Office of the Director Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) announces the availability of administrative supplements to active grants and cooperative agreements to support research on preventive interventions with populations that experience health disparities. Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent: [PA-20-272](#) - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). Application Due Date is August 1, 2022. Project budgets are limited to \$250,000 direct costs. Requests may be for up to one year of support only. Requests may be for up to one year of support only.

Funding Opportunity Announcements (FOA)

1. Molecular Dynamics of HIV (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-22-050](#)

Type:

Application Due Date: December 07, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support **computational dynamic modelling** of molecular complexes regulating the HIV life cycle, immune responses, and therapeutic interventions in HIV/AIDS using existing and new HIV and HIV/host cell structural datasets. This initiative will support integrated structural, computational, and functional approaches to study the dynamics of key molecular processes in the HIV life cycle. Applications should address a crucial component of the HIV life cycle, immunological response, or therapeutic intervention that is amenable to structural determination and dynamic modelling. Projects may not be based on purely theoretical modelling of sequence data, but instead should be centered around **datasets generated by appropriate atomic or molecular scale approaches such as NMR, electron microscopy or optical techniques**. Research projects should include iterative biologic testing and refinement of the computational models to generate an accurate and rigorous model system. Approaches affording insight at all cellular scales, from atomistic to whole-cell resolutions, are encouraged. Development of new technological innovation in modelling approaches and computational processes is highly desired, as are projects that leverage machine learning / artificial intelligence to facilitate analyses. Research teams should include computational modelers along with structural biologists, virologists, immunologists or other appropriate expertise to validate model systems. Applications that propose vertebrate animal research and/or clinical research are allowed.

Examples of research foci of interest include but are not limited to:

- HIV Env-mediated receptor binding and membrane fusion
- HIV capsid interactions with cytoplasmic and nuclear transport machinery
- HIV transcription, latency, and epigenetic regulation
- HIV genomic RNA recognition and recruitment to sites of viral assembly
- HIV assembly, budding and release
- HIV recognition by, and escape from, innate immune factors
- Binding of HIV antigens to B-cell surface immunoglobulin receptors
- Affinity maturation of anti-HIV neutralizing antibodies
- Mechanisms of action of novel anti-HIV therapeutics and their interactions with host or viral targets

Budget: NIAID intends to commit \$3,000,000 in FY 2023 to fund 3-5 awards. Application budgets are limited to \$500,000 in direct costs per year and should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Structural Biology of Alzheimer's Disease Related Dementias (ADRDs) Proteinopathies (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-208](#)

Type: R01

Application Due Date: October 07, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to continue to support studies that characterize the structure of protein aggregates found in the Alzheimer's disease related dementias (ADRD) such as alpha-synuclein, Tau, TDP-43, TMEM106B, and FUS at a high, atomic-level resolution, using approaches such as cryo-electron microscopy (cryo-EM), cryo-electron tomography (cryo-ET), and nuclear magnetic resonance (NMR) spectroscopy. Studies in response to this FOA can also include the development of research tools and resources to further characterize and validate the structural findings and their relevance to human disease. The long-term goal of this funding opportunity is for these structural studies to inform PET ligand design for these protein aggregate species and other related applications.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. Applications requesting more than \$500,000 in direct costs in any year require prior approval before submission. See Section IV "Requests of \$500,000 or more for direct costs in any year" for more instructions. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01) Clinical Trials Required

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-23-001](#)

Type: R01

Application Due Date: October 25, 2022, October 24, 2023; October 22, 2024 by 11:59 PM Eastern Time.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare diseases or conditions. Additionally, through the funding of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare diseases and exert a broad and positive impact on rare disease drug development.

Budget: Award(s) will provide one (1) year of support and include future recommended support for an additional three (3) years contingent upon annual appropriations, availability of funding, and satisfactory recipient performance. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in maximum total costs (direct and indirect costs) and maximum years of support: \$650,000 for 4 years. Applicants may request additional funding over the above listed maximums for innovative and efficient trial approaches. The additional funding request shall not exceed an additional \$250,000 total costs per year (to a maximum total award cost of \$900,000 per year) for up to 4 years. Justification for the additional funding request must be reflected in the budget request and will be reviewed annually by the program.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105